In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT

被引:109
作者
Vaneycken, Ilse [1 ,2 ]
Govaert, Jochen [3 ,4 ]
Vincke, Cecile [3 ,4 ]
Caveliers, Vicky [1 ,2 ]
Lahoutte, Tony [1 ,2 ]
De Baetselier, Patrick [3 ,4 ]
Raes, Geert [3 ,4 ]
Bossuyt, Axel [1 ,2 ]
Muyldermans, Serge [3 ,4 ]
Devoogdt, Nick [1 ,3 ,4 ]
机构
[1] Vrije Univ Brussel, Lab Vivo Cellular & Mol Imaging, B-1090 Brussels, Belgium
[2] UZ Brussel, Dept Nucl Med, Brussels, Belgium
[3] Univ Ghent VIB, Dept Mol & Cellular Interact, Brussels, Belgium
[4] Vrije Univ Brussel, Dept Cellular & Mol Immunol, B-1090 Brussels, Belgium
关键词
Tc-99m-Nanobody; humanization; CEA; SPECT/CT; biodistribution; oncology; animal imaging; SINGLE-DOMAIN ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CANCER-THERAPY; LIGHT-CHAINS; FRAGMENTS; BINDING; AFFINITY; VHH;
D O I
10.2967/jnumed.109.069823
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Nanobodies are a novel type of immunoglobulinlike, antigen-binding protein with beneficial pharmacologic and pharmacokinetic properties that are ideally suited to targeting cellular antigens for molecular imaging or therapeutic purposes. However, because of their camelid, nonhuman origin, the possible immunogenicity of Nanobodies when used in the clinic is a concern. Here we present a new strategy to quickly generate humanized Nanobodies for molecular imaging purposes. Methods: We genetically grafted the antigen-binding loops of NbCEA5, a Nanobody with specificity for the colon carcinoma marker carcinoembryonic antigen (CEA), onto the framework of a humanized Nanobody scaffold. This scaffold has been previously characterized in our laboratory as a stable Nanobody that can serve as a universal loop acceptor for antigen-binding loops from donor Nanobodies and has been additionally mutated at about 10 crucial surface-exposed sites to resemble the sequence of human variable immunoglobulin domains. The 3 recombinant Nanobodies (NbCEA5, humanized scaffold, and humanized CEA5 graft) were produced in bacteria and purified. Unlabeled and Tc-99m-labeled Nanobodies were biochemically characterized in vitro and tested as probes for SPECT/CT of xenografted tumors. Results: The success of loop-grafting was confirmed by comparing these Nanobodies for their capacity to recognize soluble CEA protein in enzyme-linked immunosorbent assay and by surface plasmon resonance and to bind to CEA-positive LS174T colon carcinoma cells and CEA-transfected but not untransfected Chinese hamster ovary cells in flow cytometry. Specificity of binding was confirmed by competition studies. All Nanobodies were heat-stable, could be efficiently labeled with Tc-99m, and recognized both soluble and membrane-bound CEA protein in binding studies. Finally, biodistribution experiments were performed with intravenously injected Tc-99m-labeled Nanobodies in LS174T tumor-bearing mice using pinhole SPECT/micro-CT. These in vivo experiments revealed specificity of tumor targeting and rapid renal clearance for all Nanobodies, with low signals in all organs besides the kidneys. Conclusion: This study shows the potency of antigen-binding loop-grafting to efficiently generate humanized Nanobodies that retain their targeting capacities for noninvasive in vivo imaging of tumors.
引用
收藏
页码:1099 / 1106
页数:8
相关论文
共 25 条
[1]   Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor [J].
Baral, Toya Nath ;
Magez, Stefan ;
Stijlemans, Benoit ;
Conrath, Katja ;
Vanhollebeke, Benoit ;
Pays, Etienne ;
Muyldermans, Serge ;
De Baetselier, Patrick .
NATURE MEDICINE, 2006, 12 (05) :580-584
[2]   Antigen binding and solubility effects upon veneering of a camel VHH in framework-2 to the mimic a VH [J].
Conrath, K ;
Vincke, C ;
Stijlemans, B ;
Schymkowitz, J ;
Decanniere, K ;
Wyns, L ;
Muyldermans, S ;
Loris, R .
JOURNAL OF MOLECULAR BIOLOGY, 2005, 350 (01) :112-125
[3]   β-lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae [J].
Conrath, KE ;
Lauwereys, M ;
Galleni, M ;
Matagne, A ;
Frère, JM ;
Kinne, J ;
Wyns, L ;
Muyldermans, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2807-2812
[4]   Efficient cancer therapy with a nanobody-based conjugate [J].
Cortez-Retamozo, V ;
Backmann, N ;
Senter, PD ;
Wernery, U ;
De Baetselier, P ;
Muyldermans, S ;
Revets, H .
CANCER RESEARCH, 2004, 64 (08) :2853-2857
[5]   Efficient tumor targeting by single-domain antibody fragments of camels [J].
Cortez-Retamozo, V ;
Lauwereys, M ;
Gh, GH ;
Gobert, M ;
Conrath, K ;
Muyldermans, S ;
De Baetselier, P ;
Revets, H .
INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (03) :456-462
[6]   Tc-99m-Labeled Nanobodies: A New Type of Targeted Probes for Imaging Antigen Expression [J].
Cortez-Retamozo, Virna ;
Lahoutte, Tony ;
Caveliers, Vicky ;
Gainkam, Lea Olive Tchouate ;
Hernot, Sophie ;
Packeu, Ann ;
De Vos, Filip ;
Vanhove, Chris ;
Muyldermans, Serge ;
De Baetselier, Patrick ;
Revets, Hilde .
CURRENT RADIOPHARMACEUTICALS, 2008, 1 (01) :37-41
[7]   CAMELISING HUMAN-ANTIBODY FRAGMENTS - NMR-STUDIES ON VH DOMAINS [J].
DAVIES, J ;
RIECHMANN, L .
FEBS LETTERS, 1994, 339 (03) :285-290
[8]   Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types [J].
De Groeve, Kurt ;
Deschacht, Nick ;
De Koninck, Celine ;
Caveliers, Vicky ;
Lahoutte, Tony ;
Devoogdt, Nick ;
Muyldermans, Serge ;
De Baetselier, Patrick ;
Raes, Geert .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (05) :782-789
[9]   Immunogenicity of protein therapeutics [J].
De Groot, Anne S. ;
Scott, David W. .
TRENDS IN IMMUNOLOGY, 2007, 28 (11) :482-490
[10]   Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody [J].
Desmyter, A ;
Decanniere, K ;
Muyldermans, S ;
Wyns, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (28) :26285-26290